Dalpiciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that plays a key role in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer. Here, NR4A1 is linked to breast cancer.